{"success":true,"data":{"pressRelease":{"id":"152720","rtpr_id":"nGNX9tvV7s-20260925","ticker":"ADXN","exchange":"","all_tickers":["ADXN"],"title":"Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior","author":"Globe Newswire","published_at":"2026-09-25T05:00:00.292Z","article_body":"Ad Hoc Announcement Pursuant to Art. 53 LR\n\nGeneva, Switzerland, September 25, 2026 - Addex Therapeutics\n(https://www.globenewswire.com/Tracker?data=rUiAfdP3vDPo7cm0Kx06gFnpdLks3MybQ4dD9CyCL5xhuqrIbVD8gvCiVH2NCnBK5CPbgPmfGAa6kO_3reIqxWiZZRE3-NoEJE91i8Na_AI73oeCes_eajZFj8GzPDY6)\n(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company\ndeveloping novel small molecule allosteric modulators for neurological\ndisorders, today announced that it has regained full global rights to all\nGABAB positive allosteric modulator (PAM) assets discovered under its research\ncollaboration with Indivior UK Limited (“Indivior”). The return of the\nrights follows Indivior’s rationalization of its research and development\nactivities and the announcement of the planned merger of Indivior’s parent\ncompany with Supernus Pharmaceuticals, Inc.\n\n\"These GABAB PAM assets reflect years of world-class research in allosteric\nmodulation and build on a biological approach clinically validated by\nbaclofen,” said Tim Dyer, CEO of Addex Therapeutics. “By regaining the\nrights to the development candidate selected by Indivior, we now have the\nflexibility to advance our broader GABAB PAM portfolio independently. This\nincludes the returned candidate for substance use disorders and our\nproprietary candidate in development for chronic cough. We can now evaluate a\nrange of strategic options, including seeking new partnerships in the near\nterm or advancing the programs further before partnering.\"\n\nThe termination of the collaboration with Indivior provides Addex with full\nownership of the returned development candidate and the freedom to pursue\ntherapeutic indications beyond those originally contemplated under the\nagreement. Combined with Addex's wholly owned GABAB PAM program for chronic\ncough, the returned asset gives the company one of the broadest portfolios\ntargeting GABAB receptor biology. The portfolio may have potential\napplications across substance use disorders, chronic cough, pain, overactive\nbladder, neurodevelopmental disorders, and other conditions in which\nmodulation of GABAB signaling has demonstrated therapeutic promise.\n\nAbout GABAB activation\nGABA is the main inhibitory neurotransmitter in the central and peripheral\nnervous systems and acts through two major receptor classes: the ionotropic\nGABAA receptor and the metabotropic GABAB receptor. GABAB receptors are widely\nexpressed throughout the nervous system and play an important role in\nregulating neuronal excitability and neurotransmission.\n\nThe therapeutic potential of GABAB receptor activation has been clinically\ndemonstrated with baclofen, a selective GABAB receptor agonist that binds to\nthe orthosteric GABA binding site. Baclofen is approved for the treatment of\nspasticity, including spasticity associated with multiple sclerosis and spinal\ncord injury. It has also been clinically investigated and used off-label\nacross a broader range of neurological, neuropsychiatric disorders and other\nconditions including alcohol use disorder and alcohol withdrawal, cocaine use\ndisorder, gastroesophageal reflux disease, and reflux-associated chronic\ncough.\n\nAlthough baclofen has demonstrated the therapeutic potential of GABAB receptor\nactivation, its broader use is constrained by aspects of its pharmacological\nand pharmacokinetics profile. These include sedation and other central nervous\nsystem side effects, as well as the potential for reduced efficacy during\nchronic treatment.\n\nGABAB PAMs offer an alternative approach to enhancing GABAB signaling. Rather\nthan binding to the orthosteric GABA-binding site, PAMs bind to a distinct\nallosteric site and enhance the receptor's response to endogenous GABA. This\nmechanism is intended to preserve the physiological and activity-dependent\nnature of GABAB receptor signaling. By enhancing the effects of endogenous\nGABA, GABAB PAMs have the potential to provide greater pathway selectivity,\nimproved tolerability and a reduced propensity for tolerance compared with\ndirect orthosteric agonism. GABAB PAMs therefore represent a promising\ntherapeutic approach for neurological, neuropsychiatric and other disorders in\nwhich modulation of inhibitory neurotransmission may provide clinical benefit.\n\nAbout Addex Therapeutics\n\nAddex Therapeutics\n(https://www.globenewswire.com/Tracker?data=rUiAfdP3vDPo7cm0Kx06gFnpdLks3MybQ4dD9CyCL5yvwJA0pMLB3yirgCldlkQis-E0KS-b9ZyGH-NB0nhffyYIVsd6V5AHlmFFtZenaIcc9yoCCGvJJUzqlVblZtOu) is\na clinical-stage biopharmaceutical company focused on developing a portfolio\nof novel small molecule allosteric modulators for neurological\ndisorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative\nallosteric modulator or NAM), is a Phase 2 ready asset under evaluation for\nfuture development in brain injury recovery, including post-stroke and\ntraumatic brain injury recovery. Addex is developing a GABAB PAM drug\ncandidate for substance use disorders that has successfully completed IND\nenabling studies and a second GABAB PAM program for chronic cough, which is\nready to start IND enabling studies. Addex holds a 20% equity interest in a\nprivate spin-out company, Neurosterix US Holdings LLC, which is advancing a\nportfolio of allosteric modulator programs, including M4 PAM for\nschizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for\nmood disorders. In addition, Addex has invested in Stalicla, a private\nSwiss company pioneering a precision medicine approach for\nneurodevelopmental and neuropsychiatric disorders.  \n\nAddex shares are listed on the SIX Swiss Exchange and American Depositary\nShares representing its shares are listed on the NASDAQ Capital Market, and\ntrade under the ticker symbol \"ADXN\" on each exchange. For more information,\nvisit www.addextherapeutics.com.\n\nContacts:\n\n Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com  Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com  \n\nAddex Forward Looking Statements:\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended, including\nstatements about the intended use of proceeds of the offering. The words\n\"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\"\n\"intend,\" \"believe,\" \"estimate,\" \"predict,\" \"project,\" \"potential,\"\n\"continue,\" \"target\" and similar expressions are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these identifying words. Any forward-looking statements in this press\nrelease, are based on management's current expectations and beliefs and are\nsubject to a number of risks, uncertainties and important factors that may\ncause actual events or results to differ materially from those expressed or\nimplied by any forward-looking statements contained in this press release,\nincluding, without limitation, uncertainties related to market conditions.\nThese and other risks and uncertainties are described in greater detail in the\nsection entitled \"Risk Factors\" in Addex Therapeutics' Annual Report on Form\n20-F, prospectus and other filings that Addex Therapeutics may make with\nthe SEC in the future. Any forward-looking statements contained in this press\nrelease represent Addex Therapeutics' views only as of the date hereof and\nshould not be relied upon as representing its views as of\nany subsequent date. Addex Therapeutics explicitly disclaims any\nobligation to update any forward-looking statements. \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e6c12443-4244-46f9-909c-5ab241bbea41)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9tvV7s-20260925","title":"Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior","author":"Globe Newswire","ticker":"ADXN","created":"2026-09-25T05:00:00.292Z","tickers":["ADXN"],"exchange":"","article_body":"Ad Hoc Announcement Pursuant to Art. 53 LR\n\nGeneva, Switzerland, September 25, 2026 - Addex Therapeutics\n(https://www.globenewswire.com/Tracker?data=rUiAfdP3vDPo7cm0Kx06gFnpdLks3MybQ4dD9CyCL5xhuqrIbVD8gvCiVH2NCnBK5CPbgPmfGAa6kO_3reIqxWiZZRE3-NoEJE91i8Na_AI73oeCes_eajZFj8GzPDY6)\n(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company\ndeveloping novel small molecule allosteric modulators for neurological\ndisorders, today announced that it has regained full global rights to all\nGABAB positive allosteric modulator (PAM) assets discovered under its research\ncollaboration with Indivior UK Limited (“Indivior”). The return of the\nrights follows Indivior’s rationalization of its research and development\nactivities and the announcement of the planned merger of Indivior’s parent\ncompany with Supernus Pharmaceuticals, Inc.\n\n\"These GABAB PAM assets reflect years of world-class research in allosteric\nmodulation and build on a biological approach clinically validated by\nbaclofen,” said Tim Dyer, CEO of Addex Therapeutics. “By regaining the\nrights to the development candidate selected by Indivior, we now have the\nflexibility to advance our broader GABAB PAM portfolio independently. This\nincludes the returned candidate for substance use disorders and our\nproprietary candidate in development for chronic cough. We can now evaluate a\nrange of strategic options, including seeking new partnerships in the near\nterm or advancing the programs further before partnering.\"\n\nThe termination of the collaboration with Indivior provides Addex with full\nownership of the returned development candidate and the freedom to pursue\ntherapeutic indications beyond those originally contemplated under the\nagreement. Combined with Addex's wholly owned GABAB PAM program for chronic\ncough, the returned asset gives the company one of the broadest portfolios\ntargeting GABAB receptor biology. The portfolio may have potential\napplications across substance use disorders, chronic cough, pain, overactive\nbladder, neurodevelopmental disorders, and other conditions in which\nmodulation of GABAB signaling has demonstrated therapeutic promise.\n\nAbout GABAB activation\nGABA is the main inhibitory neurotransmitter in the central and peripheral\nnervous systems and acts through two major receptor classes: the ionotropic\nGABAA receptor and the metabotropic GABAB receptor. GABAB receptors are widely\nexpressed throughout the nervous system and play an important role in\nregulating neuronal excitability and neurotransmission.\n\nThe therapeutic potential of GABAB receptor activation has been clinically\ndemonstrated with baclofen, a selective GABAB receptor agonist that binds to\nthe orthosteric GABA binding site. Baclofen is approved for the treatment of\nspasticity, including spasticity associated with multiple sclerosis and spinal\ncord injury. It has also been clinically investigated and used off-label\nacross a broader range of neurological, neuropsychiatric disorders and other\nconditions including alcohol use disorder and alcohol withdrawal, cocaine use\ndisorder, gastroesophageal reflux disease, and reflux-associated chronic\ncough.\n\nAlthough baclofen has demonstrated the therapeutic potential of GABAB receptor\nactivation, its broader use is constrained by aspects of its pharmacological\nand pharmacokinetics profile. These include sedation and other central nervous\nsystem side effects, as well as the potential for reduced efficacy during\nchronic treatment.\n\nGABAB PAMs offer an alternative approach to enhancing GABAB signaling. Rather\nthan binding to the orthosteric GABA-binding site, PAMs bind to a distinct\nallosteric site and enhance the receptor's response to endogenous GABA. This\nmechanism is intended to preserve the physiological and activity-dependent\nnature of GABAB receptor signaling. By enhancing the effects of endogenous\nGABA, GABAB PAMs have the potential to provide greater pathway selectivity,\nimproved tolerability and a reduced propensity for tolerance compared with\ndirect orthosteric agonism. GABAB PAMs therefore represent a promising\ntherapeutic approach for neurological, neuropsychiatric and other disorders in\nwhich modulation of inhibitory neurotransmission may provide clinical benefit.\n\nAbout Addex Therapeutics\n\nAddex Therapeutics\n(https://www.globenewswire.com/Tracker?data=rUiAfdP3vDPo7cm0Kx06gFnpdLks3MybQ4dD9CyCL5yvwJA0pMLB3yirgCldlkQis-E0KS-b9ZyGH-NB0nhffyYIVsd6V5AHlmFFtZenaIcc9yoCCGvJJUzqlVblZtOu) is\na clinical-stage biopharmaceutical company focused on developing a portfolio\nof novel small molecule allosteric modulators for neurological\ndisorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative\nallosteric modulator or NAM), is a Phase 2 ready asset under evaluation for\nfuture development in brain injury recovery, including post-stroke and\ntraumatic brain injury recovery. Addex is developing a GABAB PAM drug\ncandidate for substance use disorders that has successfully completed IND\nenabling studies and a second GABAB PAM program for chronic cough, which is\nready to start IND enabling studies. Addex holds a 20% equity interest in a\nprivate spin-out company, Neurosterix US Holdings LLC, which is advancing a\nportfolio of allosteric modulator programs, including M4 PAM for\nschizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for\nmood disorders. In addition, Addex has invested in Stalicla, a private\nSwiss company pioneering a precision medicine approach for\nneurodevelopmental and neuropsychiatric disorders.  \n\nAddex shares are listed on the SIX Swiss Exchange and American Depositary\nShares representing its shares are listed on the NASDAQ Capital Market, and\ntrade under the ticker symbol \"ADXN\" on each exchange. For more information,\nvisit www.addextherapeutics.com.\n\nContacts:\n\n Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com  Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com  \n\nAddex Forward Looking Statements:\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended, including\nstatements about the intended use of proceeds of the offering. The words\n\"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\"\n\"intend,\" \"believe,\" \"estimate,\" \"predict,\" \"project,\" \"potential,\"\n\"continue,\" \"target\" and similar expressions are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these identifying words. Any forward-looking statements in this press\nrelease, are based on management's current expectations and beliefs and are\nsubject to a number of risks, uncertainties and important factors that may\ncause actual events or results to differ materially from those expressed or\nimplied by any forward-looking statements contained in this press release,\nincluding, without limitation, uncertainties related to market conditions.\nThese and other risks and uncertainties are described in greater detail in the\nsection entitled \"Risk Factors\" in Addex Therapeutics' Annual Report on Form\n20-F, prospectus and other filings that Addex Therapeutics may make with\nthe SEC in the future. Any forward-looking statements contained in this press\nrelease represent Addex Therapeutics' views only as of the date hereof and\nshould not be relied upon as representing its views as of\nany subsequent date. Addex Therapeutics explicitly disclaims any\nobligation to update any forward-looking statements. \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e6c12443-4244-46f9-909c-5ab241bbea41)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-25T05:00:00.329482952Z","server_sent_at_ms":1790312400329},"received_at":"2026-09-25T05:00:00.379Z","source_url":null},"analysis":{"id":"141520","press_release_id":"152720","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["collaboration terminated due to partner's R&D rationalization -- no replacement funding or milestone payments disclosed","preclinical/early-stage programs; returned candidate still requires further development spend"],"eventType":"partnership","narrative":"Addex Therapeutics has regained full global rights to all GABAB positive allosteric modulator assets discovered under its research collaboration with Indivior UK Limited.\n\nThe rights return follows Indivior's R&D rationalization and its parent's planned merger with Supernus Pharmaceuticals, not any failure of the Addex assets.\n\nAddex now owns the returned development candidate for substance use disorders outright alongside its wholly owned chronic cough GABAB PAM program, and says it will evaluate new partnerships or independent advancement.\n\nNo new funding or deal value accompanies the termination, so the near-term financial impact is limited to strategic optionality.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"Addex regains full GABAB PAM rights after Indivior's Supernus-driven R&D pullback -- watch for a new partnering deal on the substance use disorder candidate."},"keyFigures":{"customDimensions":{"neurosterix_equity_stake":"20%"}},"quotedText":"We can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering.","namedEntities":{"people":[{"name":"Tim Dyer","role":"CEO of Addex Therapeutics"},{"name":"Mike Sinclair","role":"Partner, Halsin Partners (PR contact)"}],"products":["dipraglurant","GABAB PAM development candidate for substance use disorders","GABAB PAM candidate for chronic cough"],"companies":[{"name":"Addex Therapeutics","ticker":"ADXN","relationship":"filer"},{"name":"Indivior UK Limited","relationship":"former collaboration partner"},{"name":"Supernus Pharmaceuticals, Inc.","relationship":"merger partner of Indivior's parent"},{"name":"Neurosterix US Holdings LLC","relationship":"20%-owned spin-out"},{"name":"Stalicla","relationship":"private investment"},{"name":"Halsin Partners","relationship":"PR agency"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Addex regains full global rights to its GABAB PAM portfolio after the collaborator (Indivior) deprioritized R&D ahead of a merger. The return restores flexibility and partnering options but does not bring new funding, a new deal, or clinical data."},"tickerRelevance":{"others":[],"primary":"ADXN"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"rights reversion from terminated collaboration, no cash consideration","issuerAuthored":true,"strategicFlexibilityGain":true}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"neutral","material_impact_score":2,"narrative":"Addex Therapeutics has regained full global rights to all GABAB positive allosteric modulator assets discovered under its research collaboration with Indivior UK Limited.\n\nThe rights return follows Indivior's R&D rationalization and its parent's planned merger with Supernus Pharmaceuticals, not any failure of the Addex assets.\n\nAddex now owns the returned development candidate for substance use disorders outright alongside its wholly owned chronic cough GABAB PAM program, and says it will evaluate new partnerships or independent advancement.\n\nNo new funding or deal value accompanies the termination, so the near-term financial impact is limited to strategic optionality.","key_figures":{"customDimensions":{"neurosterix_equity_stake":"20%"}},"named_entities":{"people":[{"name":"Tim Dyer","role":"CEO of Addex Therapeutics"},{"name":"Mike Sinclair","role":"Partner, Halsin Partners (PR contact)"}],"products":["dipraglurant","GABAB PAM development candidate for substance use disorders","GABAB PAM candidate for chronic cough"],"companies":[{"name":"Addex Therapeutics","ticker":"ADXN","relationship":"filer"},{"name":"Indivior UK Limited","relationship":"former collaboration partner"},{"name":"Supernus Pharmaceuticals, Inc.","relationship":"merger partner of Indivior's parent"},{"name":"Neurosterix US Holdings LLC","relationship":"20%-owned spin-out"},{"name":"Stalicla","relationship":"private investment"},{"name":"Halsin Partners","relationship":"PR agency"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-25T05:00:06.588Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"rights reversion from terminated collaboration, no cash consideration","issuerAuthored":true,"strategicFlexibilityGain":true}},"durationMs":6198,"modelName":"glm-5.3-flashx"}}